Literature DB >> 24005246

Relationship between initial clinical presentation and the molecular cytogenetic classification of myeloma.

A J Greenberg1, S V Rajkumar2, T M Therneau3, P P Singh2, A Dispenzieri2, S K Kumar2.   

Abstract

Multiple myeloma (MM) consists of several distinct cytogenetic subtypes, and we hypothesized that each subtype may have a unique mode of initial presentation and end-organ damage. We studied 484 patients with newly diagnosed MM to determine the relationship between specific myeloma-defining event (MDE) and the cytogenetic subtype. Patients were divided into four non-overlapping groups based on the MDE at diagnosis: isolated renal failure, isolated anemia, isolated lytic bone disease or a combination (mixed). MM with translocations without trisomies accounted for 30% of all patients, but accounted for 50% of patients with renal failure. Specifically, the t(14;16) translocation accounted for only 5% of all MM patients, but was present in 13.5% of patients with renal failure as MDE. Among patients with t(14;16), 25% presented with renal failure only as MDE. Patients with isolated renal failure as MDE had significantly poorer survival compared with all other groups, whereas patients with bone disease as MDE had the best outcome (P<0.001). Our findings support the hypothesis that in addition to prognostic differences, there is significant heterogeneity in clinical presentation associated with the cytogenetic subtype, suggesting that MM encompasses a group of cytogenetically and phenotypically distinct disorders rather than a single entity.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24005246      PMCID: PMC3924716          DOI: 10.1038/leu.2013.258

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  21 in total

1.  Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy.

Authors:  Morie A Gertz; Martha Q Lacy; Angela Dispenzieri; Philip R Greipp; Mark R Litzow; Kimberly J Henderson; Scott A Van Wier; Greg J Ahmann; Rafael Fonseca
Journal:  Blood       Date:  2005-06-23       Impact factor: 22.113

2.  Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome.

Authors:  Hervé Avet-Loiseau; Michel Attal; Philippe Moreau; Catherine Charbonnel; Frédéric Garban; Cyrille Hulin; Serge Leyvraz; Mauricette Michallet; Ibrahim Yakoub-Agha; Laurent Garderet; Gérald Marit; Lucienne Michaux; Laurent Voillat; Marc Renaud; Bernard Grosbois; Gaelle Guillerm; Lotfi Benboubker; Mathieu Monconduit; Catherine Thieblemont; Philippe Casassus; Denis Caillot; Anne-Marie Stoppa; Jean-Jacques Sotto; Marc Wetterwald; Charles Dumontet; Jean-Gabriel Fuzibet; Isabelle Azais; Véronique Dorvaux; Marc Zandecki; Régis Bataille; Stéphane Minvielle; Jean-Luc Harousseau; Thierry Facon; Claire Mathiot
Journal:  Blood       Date:  2007-01-05       Impact factor: 22.113

3.  Prognostic value of numerical chromosome aberrations in multiple myeloma: A FISH analysis of 15 different chromosomes.

Authors:  J A Pérez-Simón; R García-Sanz; M D Tabernero; J Almeida; M González; J Fernández-Calvo; M J Moro; J M Hernández; J F San Miguel; A Orfão
Journal:  Blood       Date:  1998-05-01       Impact factor: 22.113

4.  Chromosome 13 abnormalities identified by FISH analysis and serum beta2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy.

Authors:  T Facon; H Avet-Loiseau; G Guillerm; P Moreau; F Geneviève; M Zandecki; J L Laï; X Leleu; J P Jouet; F Bauters; J L Harousseau; R Bataille; J Y Mary
Journal:  Blood       Date:  2001-03-15       Impact factor: 22.113

5.  A validated FISH trisomy index demonstrates the hyperdiploid and nonhyperdiploid dichotomy in MGUS.

Authors:  Wee Joo Chng; Scott A Van Wier; Gregory J Ahmann; Jerry M Winkler; Syed M Jalal; Peter Leif Bergsagel; Marta Chesi; Mike C Trendle; Martin M Oken; Emily Blood; Kim Henderson; Rafael Santana-Dávila; Robert A Kyle; Morie A Gertz; Martha Q Lacy; Angela Dispenzieri; Philip R Greipp; Rafael Fonseca
Journal:  Blood       Date:  2005-05-26       Impact factor: 22.113

6.  Testing standard and genetic parameters in 220 patients with multiple myeloma with complete data sets: superiority of molecular genetics.

Authors:  John D Shaughnessy; Jeffrey Haessler; Frits van Rhee; Elias Anaissie; Mauricio Pineda-Roman; Michele Cottler-Fox; Klaus Hollmig; Maurizio Zangari; Abid Mohiuddin; Yazan Alsayed; Monica Grazziutti; Joshua Epstein; John Crowley; Bart Barlogie
Journal:  Br J Haematol       Date:  2007-05-09       Impact factor: 6.998

7.  Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy.

Authors:  J Drach; J Ackermann; E Fritz; E Krömer; R Schuster; H Gisslinger; M DeSantis; N Zojer; M Fiegl; S Roka; J Schuster; R Heinz; H Ludwig; H Huber
Journal:  Blood       Date:  1998-08-01       Impact factor: 22.113

Review 8.  Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma.

Authors:  R A Kyle; S V Rajkumar
Journal:  Leukemia       Date:  2008-10-30       Impact factor: 11.528

9.  Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma.

Authors:  S V Rajkumar; V Gupta; R Fonseca; A Dispenzieri; W I Gonsalves; D Larson; R P Ketterling; J A Lust; R A Kyle; S K Kumar
Journal:  Leukemia       Date:  2013-03-21       Impact factor: 11.528

10.  Deletion of chromosome band 13q14 as detected by fluorescence in situ hybridization is a prognostic factor in patients with multiple myeloma who are receiving allogeneic dose-reduced stem cell transplantation.

Authors:  Nicolaus Kröger; Georgia Schilling; Hermann Einsele; Peter Liebisch; Avichai Shimoni; Arnon Nagler; Jose A Perez-Simon; Jesus F San Miguel; Michael Kiehl; Axel Fauser; Rainer Schwerdtfeger; Hannes Wandt; Herbert G Sayer; Han Myint; Hans Klingemann; Tatjana Zabelina; Judith Dierlamm; Axel Hinke; Axel R Zander
Journal:  Blood       Date:  2004-02-24       Impact factor: 22.113

View more
  28 in total

1.  Challenges and Promises of Genetic Stratification of Risk in Multiple Myeloma.

Authors:  Hara Prasad Pati; Prashant Sharma
Journal:  Indian J Hematol Blood Transfus       Date:  2017-01-16       Impact factor: 0.900

Review 2.  Current Review on High-Risk Multiple Myeloma.

Authors:  Henry S H Chan; Christine I Chen; Donna E Reece
Journal:  Curr Hematol Malig Rep       Date:  2017-04       Impact factor: 3.952

Review 3.  Role and mechanism of action of sclerostin in bone.

Authors:  Jesus Delgado-Calle; Amy Y Sato; Teresita Bellido
Journal:  Bone       Date:  2016-10-12       Impact factor: 4.398

4.  The colorful landscape of multiple myeloma.

Authors:  Eli Muchtar; Morie A Gertz
Journal:  Leuk Lymphoma       Date:  2019-02-27

5.  The role of initial clinical presentation, comorbidity and treatment in multiple myeloma patients on survival: a detailed population-based cohort study.

Authors:  B E Oortgiesen; E N van Roon; P Joosten; R E Kibbelaar; H Storm; S Hovenga; B van Rees; G Woolthuis; N Veeger; E G de Waal; M Hoogendoorn
Journal:  Eur J Clin Pharmacol       Date:  2017-03-03       Impact factor: 2.953

6.  Osteolytic lesions, cytogenetic features and bone marrow levels of cytokines and chemokines in multiple myeloma patients: Role of chemokine (C-C motif) ligand 20.

Authors:  B Dalla Palma; D Guasco; M Pedrazzoni; M Bolzoni; F Accardi; F Costa; G Sammarelli; L Craviotto; M De Filippo; L Ruffini; P Omedè; R Ria; F Aversa; N Giuliani
Journal:  Leukemia       Date:  2015-09-30       Impact factor: 11.528

Review 7.  Myeloma today: Disease definitions and treatment advances.

Authors:  S Vincent Rajkumar
Journal:  Am J Hematol       Date:  2016-01       Impact factor: 10.047

8.  Hypercalcaemia, renal dysfunction, anaemia and bone lesions (CRAB) do not always represent multiple myeloma: diffuse large B cell lymphoma presenting with CRAB symptoms in a 69-year-old man.

Authors:  Hafez Mohammad Ammar Abdullah; Moataz Ellithi; Qazi Waqas; Arwyn Cunningham; Tony Oliver
Journal:  BMJ Case Rep       Date:  2019-08-04

Review 9.  Mechanisms of osteolytic and osteoblastic skeletal lesions.

Authors:  G David Roodman; Rebecca Silbermann
Journal:  Bonekey Rep       Date:  2015-10-28

10.  Bidirectional Notch Signaling and Osteocyte-Derived Factors in the Bone Marrow Microenvironment Promote Tumor Cell Proliferation and Bone Destruction in Multiple Myeloma.

Authors:  Jesus Delgado-Calle; Judith Anderson; Meloney D Cregor; Masahiro Hiasa; John M Chirgwin; Nadia Carlesso; Toshiyuki Yoneda; Khalid S Mohammad; Lilian I Plotkin; G David Roodman; Teresita Bellido
Journal:  Cancer Res       Date:  2016-02-01       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.